This invention involves a series of engineered derivatives of the KOS-37 BAC, a bacterial artificial chromosome carrying a complete herpes simplex virus type 1 (HSV-1) genome.
Description
These derivatives are designed to target and destroy cancer cells, specifically glioblastoma, by using modified viral vectors that can selectively infect and kill tumor cells while sparing healthy tissue. This innovative approach has the potential to significantly improve cancer treatment outcomes by providing a more targeted and less toxic alternative to traditional therapies.
Applications
• Glioblastoma
• Other Solid Tumors
• Metastatic Cancers
• Brain Cancer
Advantages
The targeted oncolytic vectors offer several advantages over existing cancer therapies. Unlike traditional chemotherapy and radiation, which can damage healthy cells and cause significant side effects, these vectors are designed to selectively infect and kill cancer cells. This specificity reduces collateral damage to healthy tissue and minimizes side effects. Additionally, the vectors can be engineered to express therapeutic genes or immune-modulating agents, enhancing their anti-tumor efficacy. For example, the inclusion of microRNA response sequences in the vectors helps to block off-target replication, increasing the safety of the treatment. The deletion of residue 38 in the gD gene of the HSV vector prevents reversion to a more virulent form, ensuring the stability and effectiveness of the therapy.
Invention Readiness
The targeted oncolytic vectors are currently at the in vivo data stage, indicating that they have been tested in animal models with promising results. The next steps in development include further preclinical testing to confirm safety and efficacy, followed by clinical trials to evaluate the treatment in human patients. Continued development and validation of these vectors will be crucial in advancing them towards clinical use and ultimately improving cancer treatment outcomes.
IP Status
Research Tool
